Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and RNA Processing Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CPSF3 Wild-type and Mutant Proteins (Full-length or Nuclease Domain) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Suitable for biochemical and SPR assays. |
View CPSF3 Products |
| Gene Delivery | CPSF3 ORF Clone / Lentivirus Particles Full-length ORF for stable cell line construction. HEK293T packaging. |
View CPSF3 Products |
| Benchmark Antibody | Anti-CPSF3 Reference Antibody Recombinant positive control for assay standardization. |
View CPSF3 Products |
| Resistance Panel | CPSF3 Mutant Proteins (Active Site Variants) For mechanism and resistance profiling. Sequence verified. |
View CPSF3 Products |
| Validator | CPSF3 siRNA Set (3 unique sequences) For knockdown verification (>70% efficiency) and specificity controls. |
View CPSF3 Products |
| Related Target A | MYC Oncogenic driver conferring transcription addiction and synergistic dependency on CPSF3. |
View MYC Products |
| Related Target B | WDR33 Direct interaction partner within the mCF complex essential for RNA processing. |
View WDR33 Products |
| Complex Partner | CPSF1 (Cleavage Polyadenylation Specificity Factor) Subunit interaction studies, complex formation assays. |
View CPSF1 Products |
| Pathway Associate | CSTF2 (Cleavage Stimulation Factor Subunit 2) Alternative polyadenylation pathway component. |
View CSTF2 Products |
| Off-Target Control | CPSF2 (Cleavage Polyadenylation Specificity Factor) Paralog specificity testing, selectivity assays. |
View CPSF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Validation | High-purity (>95%) CPSF3 Nuclease Domain expressed in HEK293 (Native folding). Sequence Verified. Suitable for biochemical assays. |
| Resistance Mechanism Profiling | Custom Mutant Protein Generation: Active site variants available with sequence verification. For mechanism-of-resistance studies. |
| Paralog Selectivity Screening | Homolog Panel Available: CPSF1, CPSF2 proteins with >95% purity for counter-screening. Mass spec verified identity. |
| Cellular APA Assays | Validated siRNA Set: Three unique sequences with guaranteed knockdown efficiency (>70%) for use as positive controls in APA reporter assays. |
| Complex Formation Studies | Full-length ORF Lentivirus: For stable integration and co-expression studies with CPSF complex partners. |
| Standardization and False Positive Control | Recombinant reference antibodies included for benchmark establishment; validated siRNA for specificity checks and genetic knockdown baselines. |
Live CPSF3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CPSF3 therapeutics is accelerating, driven by its critical role in pre-mRNA 3' end processing as the endonuclease component of the cleavage and polyadenylation specificity factor complex. CPSF3 has emerged as a major synthetic lethal target in transcription-addicted cancers such as acute myeloid leukemia (AML), Ewing sarcoma, and spliceosome-mutant solid tumors. Current development predominantly focuses on small molecule inhibitors (e.g., JTE-607 derivatives) aimed at the nuclease active site, with first-generation compounds reaching Phase I/II trials. The next wave of R&D is targeting resistance mutation profiling, synthetic lethal combinations (e.g., with Bcl-2 antagonists or transcription inhibitors), and novel modalities such as molecular glue degraders that recruit CPSF3 to specific RNA targets. Overcoming primary resistance mutations and achieving selectivity over paralogs (CPSF1, CPSF2) are key challenges.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Bayer, AstraZeneca, Biotech startups | AML, Solid Tumors (Ewing Sarcoma, Ovarian Cancer) | Enzymatic Activity Assay (Need high-purity nuclease domain protein) |
| Targeted Protein Degradation (PROTAC/Molecular Glue) | Targeted degradation companies | MYC-driven cancers, Refractory Solid Tumors | Cell Line Construction (Lentivirus for stable CPSF3 expression); Ternary Complex Assays |
| RNAi / Antisense | Gene therapy companies | Hematological Malignancies | Knockdown Validation (Need standardized siRNA and Reference Abs) |
| Synthetic Lethal Combinations | Oncology-focused biotechs | Spliceosome-mutant cancers | Combination toxicity and synergy studies (siRNA for validation; lentivirus for stable KD) |
| Allosteric Modulators | Early discovery programs | Hematologic Malignancies | Mutant vs WT Selectivity (Resistance mutant proteins) |